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 Trials Assessing Parmacotherapeutic Management of 
Aggression in Psychiatric Patients: Comparability with 
Clinical Practice 
in daily practice would qualify for trial participa-
tion when applying exclusion criteria that are 
commonly used in RCTs. Another recent study 
showed that in patients suﬀ ering from epilepsy, 
less than thirty percent would qualify to partici-
pate in a standard RCT  [39] . 
 In the present study we aim to determine the 
comparability of patients in RCTs investigating 
the maintenance pharmacotherapy for those 
patients in whom aggression is an ongoing prob-
lem, with patients of psychiatric long-stay 
wards. 
 Patients and Methods 
 ▼ 
 RCTs 
 In a previously published paper, we reviewed the 
literature for RCTs assessing the pharmacothera-
peutic maintenance therapy of aggression  [18] . 
In brief, these trials were retrieved by searching 
Pubmed, EMBASE, Psyclit and Cochrane up to 
March 2004, using MESH terms covering both 
 “ aggression ” (including aggression-related symp-
toms like violence) and pharmacotherapy 
(including the diﬀ erent psychotropic drug 
classes). These RCTs  [1 – 3,  5 – 13,  15 – 17,  19,  20,  23 –
 Introduction 
 ▼ 
 Aggression is an important issue in mental health 
departments, as it negatively infl uences the well-
being of both patients and staﬀ  workers and 
results in high costs  [4,  21] . Pharmacotherapy is 
one of the tools used to prevent or reduce aggres-
sive behaviour and incidents. Our group has 
shown that only weak empirical evidence is 
available for the eﬀ ectiveness of pharmacothera-
peutic management of aggression  [18] . This sys-
tematic review was restricted to randomized 
controlled trials (RCTs) as these are considered to 
be the gold standard to obtain the most valid evi-
dence for the eﬀ ect of interventions  [38] . How-
ever, one of the observations from the review 
was that characteristic aggressive patients seen 
in clinical practice may be diﬀ erent from those 
included in RCTs, because of recruitment proce-
dures depending on voluntary participation, 
strict inclusion and exclusion criteria, and some-
times small populations. This selection process 
may hamper the comparability of RCT popula-
tions to daily clinical practice patients, as has 
been shown by others, especially in psychiatric 
populations. Zimmerman  [44] , for example, 
showed that only 14  % of depressed patients seen 
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 Abstract 
 ▼ 
 Introduction:  In a previous review of rand-
omized controlled trials (RCTs) on the phar-
macotherapeutic management of aggression, 
it was shown that there is only weak evidence 
of eﬀ ectiveness. In the present study we aim to 
determine comparability of patients included in 
these RCTs and patients of psychiatric long-stay 
wards. 
 Methods:  Exclusion criteria that were used in 
at least 20  % of the RCTs were applied to a sample 
of aggressive inpatients from clinical practice, in 
order to fi nd what proportion of these patients 
would be eligible to participate in the reviewed, 
high quality RCTs.  
 Results:  Only 30  % of aggressive psychiatric 
patients as seen in clinical practice would be eli-
gible to participate in a typical randomized con-
trolled trial based on the most frequently applied 
exclusion criteria. 
 Discussion:  The low comparability of patients 
included in RCTs with those seen in clinical prac-
tice may decrease the generalizability of the 
fi ndings form RCTs to clinical practice. 
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 30,  32 – 37,  40 – 43] studied the pharmacological management of 
aggression in adult (18 – 65 years old) psychiatric patients in gen-
eral psychiatric settings. This means that RCTs applying to spe-
cialized psychiatric settings  – like child psychiatry, mental 
retardation, and organic brain diseases  – or to non-psychiatric 
settings  – like prisons  – were not included in this review. For this 
review, only those RCTs of suﬃ  cient methodological quality, 
which was defi ned as a Jadad score  [22] of three or more, were 
selected for the present study. 
 The selected 31 RCTs  [1 – 3,  5 – 8,  10 – 13,  17,  19,  20,  23 – 25,  27 –
 30,  32 – 37,  40 – 43] with suﬃ  cient quality were reviewed for 
applied exclusion criteria. 
 Clinical practice sample 
 The population sampled from clinical practice consisted of all 
patients of three long-stay wards of Altrecht Mental Health Care 
Institute who engaged in aggressive behaviour during admis-
sion. The three participating wards were units for forensic psy-
chiatry, a centre for intellectually disabled adolescents and 
adults with severe disruptive behaviour, and a ward for juveniles 
with externalizing behaviour disorders. Aggressive behaviour on 
these wards was continuously monitored and recorded by the 
staﬀ  using the staﬀ  observation aggression scale-revised (SOAS-
R)  [31] . Patients eligible for our study populations had all had 
been admitted for at least two weeks during the period Septem-
ber 2004 until December 2005. Patients with one or more 
aggressive incidents during the study period, as recorded with 
the SOAS-R, were selected. 
 For consenting patients, physical examination, medical history 
and laboratory values were determined during the fi rst week of 
admission. These data as well as demographic information were 
extracted from the hospital records. 
 The study protocol was approved by the Institutional Review 
Board of the hospital. 
 Data analysis 
 All selected RCTs were reviewed and all exclusion criteria that 
were used in at least six (20  % ) of the 31 RCTs were selected. Sub-
sequently, these criteria were applied to the sample of aggres-
sive inpatients from clinical practice, in order to calculate what 
proportion of these patients would be eligible to participate in 
the reviewed, high quality RCTs. Lastly, characteristics of eligible 
patients were compared with characteristics of ineligible 
patients. 
 As the patients from clinical practice were all inpatients, a sub-
analysis, with the use of only the exclusion criteria used in at 
least 20  % of the RCTs conducted in inpatient settings, was per-
formed. 
 Results 
 ▼ 
 RCTs 
 The RCTs were conducted in the following patient groups: schiz-
ophrenic patients (N  =  12 [39  % of the RCTs]) and patients with 
cluster B personality disorder (N  =  12 [39  % of the RCTs), patient 
ssuﬀ ering from PTSD (N  =  3 [10  % of the RCTs]), depressive disor-
der (N  =  2 [7  % of the RCTs]), ADHD (N  =  1 [3  % of the RCTs]) and 
autistic disorder (N  =  1 [3  % of the RCTs]). 
 The exclusion criteria extracted from the RCTs are presented 
in   ● ▶  Table 1 . 
 A number of exclusion criteria, including  “ relevant somatic dis-
order ” ,  “ physical disorder ” ,  “ unstable medical disease ” and 
 “ abnormal routine lab ” , were generally not well-defi ned. The 
authors of studies in which these exclusion criteria were not 
well-defi ned, were contacted by e-mail for further specifi cation 
of these criteria. Response rate was low (3 out of 15  =  20  % ). On 
basis of the responses and the other reviewed RCTs in which 
somatic illnesses or deviant laboratory values as exclusion crite-
ria were defi ned more precisely, we decided to further specify 
the criteria as follows:  “ relevant somatic disorder ” ,  “ physical 
disorder ” and  “ unstable medical disease ” included neurological 
diseases, COPD and asthma, cardiovascular disease, liver disease 
and renal failure, whereas  “ abnormal routine lab ” comprised 
deviant laboratory tests fi ndings, including liver function, kid-
ney function, thyroid function and haemogramme. 
 The exclusion criterion  “ the use of psychotropics other than the 
study medication ” was used in 58  % of the trials with borderline 
 Table 1  Exclusion criteria used in the RCTs. 
 Exclusion criteria  Percentage of all trials in which 
the  criterion was used 
 Percentage of trials, conducted in inpatient 
setting, in which the criterion was used 
 substance abuse (alcohol or drugs)  54.8  44.4 
 abnormal routine laboratory values  51.6  66.7 
 clinically relevant systemic somatic disorder (heart, renal, 
hepatic, neurological, asthma and COPD) 
 51.6  61.1 
 pregnancy  38.7  33.3 
 use of other psychotropics than the study drug  35.5  16.7 
 lactating  32.2  27.8 
 suicidal ideation  19.3  0.0 
 without contraception  16.1  11.1 
 unstable medical disorder  16.1  16.7 
 organic brain disorder  9.7  38.9 
 psychotherapy  9.7  0.0 
 depot neurolepticum  9.7  16.7 
 women  6.4  0.0 
 men  3.2  0.0 
 history of psychiatric hospitalization  3.2  0.0 
 IQ   <  75  3.2  5.6 
 drug-induced psychosis  3.2  5.6 
 self-mutilation  3.2  0.0 
Review
 Goedhard LE et  al. Trials Assessing Parmacotherapeutic Management  …  Pharmacopsychiatry 
patients, but in none of the trials conducted in a study popula-
tion consisting of schizophrenic patients. 
 Clinical practice sample 
 The clinical practice sample consisted of 106 aggressive patients. 
Patients ’ characteristics are displayed in   ● ▶  Table 2 . Exclusion 
criteria were applied in descending order of appearance in the 
trials. Current drugs and / or alcohol abuse was observed in 29  % 
of the patients. Fourteen patients (13  % ) had a relevant somatic 
disorder. Furthermore, three patients (3  % ) refused to undergo a 
physical examination, which would be reason for exclusion in an 
RCT. Abnormal routine lab was observed in 13  % of the patients, 
whereas 5  % of the patients refused to give a blood sample. No 
patients were pregnant or lactating. Finally, in several studies 
patients were excluded if other psychotropics were used con-
comitantly with the study drug. We assumed that patients from 
our study sample using two or more psychotropics would not 
likely be switched to only one study-drug. Therefore, from our 
study sample patients using more than one psychotropic, i.  e., 
almost one third (34  % ), were considered ineligible for a trial. 
 With the application of these criteria on the study population, 
only 30  % of the patients would be eligible for trial participation 
(  ● ▶  Fig. 1 ). As use of other psychotropics was not a frequently 
used exclusion criterion in the RCTs conducted in patients with 
schizophrenia, we also calculated the percentage of eligible 
schizophrenic patients, without application of this criterion, 
which resulted in a percentage of 43  % of patients that would be 
eligible. 
 Lastly, in the subanalysis in which only exclusion criteria of the 
RCTs conducted in inpatients setting were applied to the clinical 
practice sample, 46  % of patients appeared to be eligible. 
 Eligible versus ineligible patients 
 The eligible patients were compared with the ineligible patients, 
results of this comparison are shown in   ● ▶  Table 3 . 
 Eligible patients were signifi cantly younger and were less fre-
quently diagnosed with a personality disorder. Concerning the 
All aggressive patients
N = 106 (100%) 
Exclusion of patients with substance abuse 
Exclusion of patients with a relevant somatic disorder 
Exclusion of patients with abnormal routine laboratory values 
Exclusion of pregnant patients
Exclusion of patients using two or more psychotropics 
Exclusion of lactating patients 
N = 49 (46.2%) 
N = 49 (46.2%) 
N = 32 (30.2%) 
N = 32 (30.2%) 
N = 62 (58.5%) 
N = 75 (70.8%) 
 Fig. 1  Sequential application of exclusion criteria to the whole group of 
patients. 
 Table 2  Clinical practice sample.  Characteristic  Patients with aggressive incident (s) (n  =  106) 
 age (mean, SD)  27.3  (10.4) 
 aggressive incidents per month (mean, SD)  1.9  (4.2) 
  No.  (  % ) 
 male sex  76  (71.7) 
 diagnosis (DSM IV) 
 – Axis I 
  – psychotic disorder  49  (46.2) 
  – mood disorder  11  (10.4) 
  – anxiety  6  (8.8) 
  – alcohol dependence / abuse  9  (8.5) 
  – drug dependence / abuse  27  (25.5) 
  – pervasive disorder  10  (9.4) 
  – ADHD  & disruptive behaviour  24  (22.6) 
  – other  11  (10.4) 
 – Axis II 
  – personality disorder  14  (13.2) 
  – mental retardation  40  (37.7) 
 regular medication use 
 – antidepressants  18  (17.0) 
 – antipsychotics  54  (50.9) 
 – benzodiazepines  33  (31.1) 
 – mood stabilizer  11  (10.4) 
 – somatic medication  33  (31.1) 
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frequency and severity of aggression, no diﬀ erences were 
observed between eligible and ineligible patients. 
 Discussion 
 ▼ 
 The current results suggest that, based upon the most frequently 
applied exclusion criteria, only 30  % of aggressive psychiatric 
patients as seen in clinical practice would be eligible to partici-
pate in a typical randomized controlled trial investigating the 
pharmacological maintenance treatment of aggression. This 
fi nding is in line with the proportions reported in two previous 
studies, in which 14  % and 30  % of patients from clinical practice 
were found to be eligible for trial participation in a clinical prac-
tice population treated for depression and epilepsy, respectively 
 [39,  44] . 
 These fi ndings warrant the conclusion that the evidence for the 
pharmacological management of aggression not only appears to 
be weak  [18] but that, additionally, the patients in trials are dif-
ferent from the patients of clinical practice, or at least diﬀ erent 
from typical psychiatric long-stay inpatients. Subsequently this 
raises the question whether the trial outcomes are generalizable 
to clinical practice. It is quite well imaginable that they are not. 
For example, it is likely that more somatic comorbidity infl u-
ences the generalizability of trials, e.  g., due to the use of co-
medication. Furthermore, comparison of the group of the eligible 
with the non-eligible patients shows that the eligible patients 
diﬀ er from the non-eligible patients, at least for diagnosis and 
age. 
 In addition to the exclusion criteria applied, other characteris-
tics of the evaluated RCTs are likely to decrease the comparabil-
ity of trials to clinical practice. Firstly, previous research suggests 
that aggressive patients are less likely to give informed consent 
 [14] . This might lead to an underrepresentation of severely 
aggressive patients. Furthermore, the setting of many RCTs 
( ~ 40  % in outpatient departments) and the recruitment methods 
(e.  g., advertisement) might also have contributed to an under-
representation of severely aggressive patients in the RCTs. It is 
well imaginable that the aetiology of aggression of severely 
aggressive patients diﬀ ers from the aetiology in mildly aggres-
sive patients, thereby requiring diﬀ erent pharmacotherapeutic 
strategies. 
 In conclusion, it is likely that the low comparability of the 
patients in RCTs with the patients from practice aﬀ ects the gen-
eralizability of the eﬃ  cacy of trial medication and observed side 
eﬀ ects. However, with the available data we were not able to 
investigate this. To investigate this, other research, such as con-
ducted by Wisniewski et  al.  [45] , is needed. In that study the 
researchers showed that depressive patients who would be inel-
igible for a phase III trial with antidepressants, experienced 
more severe side eﬀ ects and had lower remission and response 
rates compared to the eligible patients. 
 From a clinical point of view we therefore conclude that it might 
be understandable that with only weak evidence for eﬃ  cacy, 
psychotropics are used (oﬀ -label) in an attempt to manage such 
a diﬃ  cult behaviour as aggression. However, from our point of 
view, prescribers should be well aware of the limited available 
evidence with a probable low generalizability to clinical prac-
tice, and certainly stop the medication if no eﬀ ect is observed. 
 This study has some limitations. The criterion  “ multiple psycho-
tropic use ” was observed in the trials conducted in populations 
consisting of patients with cluster B personality disorder, but 
not in the trials conducted in populations consisting of schizo-
phrenic patients. The percentage of patients that could be 
included in a study would increase to 46  % if multiple psycho-
tropic use would be allowed. This suggests that an analysis, 
stratifi ed for diagnosis would be more appropriate. However, the 
number of included trials was not enough to conduct such an 
analysis. 
 Furthermore, because the methodology of the trials was not 
always clearly described, we may have interpreted the criteria 
concerning somatic disorders and abnormal routine laboratory 
values not strictly enough or too strictly when cut-oﬀ  points 
were not mentioned in the RCTs. Future studies possibly could 
give more insight, with the current regulations binding research-
ers to publish their study protocols in an internet database. 
 Conclusion 
 ▼ 
 With an eligibility percentage of 30 – 46  % , we conclude that the 
patient comparability of trials, investigating the pharmacologi-
cal management of aggression, to clinical practice is low. Fur-
thermore, other RCT characteristics suggest that patients 
displaying severe aggression are not eligible in RCTs. The low 
comparability may decrease the generalizability of RCT fi ndings 
to clinical practice. 
 Table 3  Comparison of eligible and ineligible patients. 
 Characteristic  Included patients  Excluded patients  P-value 
  N  (  % )  N  (  % )  
 age (mean, SD)  23.5  9.9  28.9  10.3  0.003 
 aggressive incidents per 100 days (median)  4.2   2.5   0.19 
 severely aggressive  28  (87.5)  55  (74.3)  0.13 
 male sex  20  (62.5)  56  75.7  0.17 
 diagnosis (DSM IV) 
 – axis I 
  – psychotic disorder  11  (34.4)  38  (51.4)  0.11 
  – mood disorder  4  (12.5)  7  (9.5)  0.64 
  – pervasive disorder  6  (18.8)  4  (5.4)  0.06 
  – ADHD  & disruptive behaviour  11  (34.4)  13  (17.6)  0.06 
 – axis II 
  – personality disorder  2  (6.2)  17  (23)  0.04 
  – mental retardation  10  (31.2)  30  (40.5)  0.37 
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